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ABSTRACT
The multistructural and multifunctional transmembrane glycoprotein CD44 is 
overexpressed in many tumors of distinct origin including malignant melanoma and 
contributes to a poor prognosis by affecting cell proliferation, cell migration, and 
also the sensitivity for apoptosis induction. Previous studies reported so far 15 CD44 
regulatory microRNAs (miRs) in different cell systems.
Using a novel method for miR affinity purification miR-143-3p was identified as 
most potent binder to the 3’ untranslated region (UTR) of CD44. Overexpression of 
miR-143-3p in melanoma cells inhibits CD44 translation, which is accompanied by 
a reduced proliferation, migration and enhanced daunorubicin induced apoptosis of 
melanoma cells in vitro.
Analyses of discordant CD44 and miR-143-3p expression levels in human 
melanocytic nevi and dermal melanoma samples demonstrated medium to high CD44 
levels with no association to tumor grading or staging. The CD44 expression correlated 
to PD-L1, but not to MART-1 expression in malignant melanoma. Interestingly, the 
CD44 expression was inversely correlated to the infiltration of pro-inflammatory 
immune effector cells.
In conclusion, the tumor suppressive miR-143-3p was identified as the most 
potent CD44 inhibitory miR, which affects growth characteristics of melanoma cells 
suggesting the implementation of miR-143-3p as as a potential anti-CD44 therapy of 
malignant melanoma.
INTRODUCTION
The transmembrane glycoprotein CD44 is constitutively 
expressed on embryonic stem cells, in connective tissues and in 
the bone marrow and overexpressed in different tumor entities 
as well as in cancer stem cells (CSC). Upon binding to its 
ligand, the extracellular matrix (ECM) component hyaluronic 
acid (HA), CD44 plays a key role in various physiological 
functions by activating different signal transduction pathways 
leading to cell proliferation, adhesion, migration, angiogenesis 
and inflammation [1–3], but also in pathophysiologic 
processes, such as self-renewal, tumor initiation, epithelial 
mesenchymal transition, metastasis and chemoresistance [4, 5]. 
Furthermore, CD44 has been suggested as a diagnostic marker 
for CSC and as a prognostic marker for different tumor entities 
correlating with a poor prognosis of tumor patients [4, 6].
The human CD44 gene is highly conserved, 
localized on the short arm of chromosome 11 and encoded 
by 20 exons, from which 10 are constant in all isoforms 
[7]. The “standard” CD44 isoform (CD44s) encoded by 
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the 10 constant exons has a molecular weight of 85–90 
kDa and is ubiquitously expressed in vertebrates. The 
“variant” isoforms (CD44v) are generated by alternative 
splicing and comprise next to the 10 constant exons any 
combination of the remaining variant exons forming 42 
currently known CD44 isoforms at the mRNA level, of 
which 29 encode for proteins [8, 9]. In contrast to CD44s, 
the distribution of CD44v isoforms is restricted to selected 
epithelial, proliferating and even tumor cells [2, 10, 11].
The diversity of the CD44 protein family is 
mediated by alternative splicing, and by posttranslational 
modifications, including massive glycosylation and 
domain cleavage. These properties highly increase 
the functional variety and binding capacity of CD44 
[4]. In addition, the CD44 gene expression is post-
transcriptionally regulated by microRNAs (miRs), which 
are small, highly conserved, non-coding RNAs that 
preferentially bind to the 3‘untranslated region (UTR) of 
the target mRNA leading to mRNA decay and translational 
inhibition [12]. So far, at least 15 different CD44-
regulating miRs have been identified mainly exhibiting 
tumor suppressive activities by exerting anti-proliferative, 
anti-invasive, anti-angiogenic and apoptosis-promoting 
functions (Table 1; [13, 14, 23–26, 15–22]).
Malignant melanoma (MM) is one of the 
most aggressive neoplasms derived from malignant 
transformation of melanocytes with an increasing 
incidence worldwide over the decades. The main risk 
factors include exposure to ultraviolet (UV) light, genetic 
susceptibility and the number of melanocytic nevi [47, 
48]. With the introduction of immunotherapy and targeted 
therapies the outcome of patients increased due to response 
rates of 20–40% [49]. However, there is still an urgent 
need for biomarkers to distinguish therapy responders 
from non-responders and also of novel therapeutic targets.
While melanocytes only express CD44s, benign 
melanocytic lesions, melanoma lesions and melanoma 
cell lines heterogeneously express both CD44s as well 
as CD44v isoforms [27, 28]. Interestingly, patients with 
higher (pan)CD44 expression had a significant reduced 
5-years’ overall survival (OS). Targeting of CD44 in 
experimental models in vivo resulted in an increased 
survival rate of mice [29]. Investigations regarding the 
potential of CD44 as therapeutic target used multiple 
approaches, including monoclonal antibodies (mAb) 
[30], peptides like A5G27 or PEX9 [31, 32] and post-
transcriptional down regulation by RNAi [33]. Currently, 
miRs are of growing interest, not only as diagnostic, 
prognostic or predictive biomarkers, but also as 
therapeutic tools. So far, 15 human CD44 regulatory miRs 
have been identified in various cell systems (Table 1), but 
their functional relevance has not yet been determined. 
Therefore, these miRs were characterized regarding their 
binding affinity to the 3’ UTR of CD44s, their tumor 
biological functions and their potential as putative miR-
based anti-cancer drug in melanoma.
RESULTS
Despite more than 15 CD44 regulatory miRs have 
been reported in the literature (Table 1). There exists so far 
no information about their affinity to the CD44 3’ UTR in 
general and in particular for melanoma cells. Therefore, 
the affinity of these miRs was validated and compared 
to the reported binding sites within the CD44 3’ UTR by 
using a novel miR-specific enrichment assay (Figure 1A).
The eluates of this affinity purification were 
analyzed by qPCR. The interaction between the HLA-G 
3’ UTR and miR-152 served as positive control [38]. As 
expected, miR-152 was statistically significant enriched 
with the HLA-G 3’ UTR as bait, but not with the two 
fragments (#A and #B) of the CD44 3’ UTR (Figure 1B). 
MiR-141 as a negative control was present in the applied 
cell lysate (input), but neither enriched with the HLA-G 3’ 
UTR nor with the CD44 3’ UTR (Figure 1C). Concerning 
the affinity purification of the known CD44 regulatory 
miRs, miR-34A-5p and miR-143-3p were highly enriched 
with the CD44 3’ UTR as bait when compared to the 
HLA-G 3’ UTR, which was statistically significant for 
miR-143-3p (Figure 1D–1E). The miR-199A and miR-491 
were also enriched, but to a weaker extent (Figure 1F–
1G), while the other reported CD44 regulatory miRs were 
not enriched with the reported CD44 3’ UTR fragment. 
However, an interaction of these miRs with the coding 
sequence or the 5’ UTR of the CD44 mRNA cannot be 
excluded. Despite these miRs were published as binding to 
the investigated CD44 3’ UTR, they were excluded from 
further experiments. The miR-541-3p was not expressed 
in the applied cell lysate.
Ten melanoma cell lines were investigated for their 
CD44s expression using flow cytometry (Figure 2A). The 
BLM, WM1552C, and A375 cell lines exerted the highest 
CD44s expression levels. Due to the high transfection 
efficacy the BLM cell line was selected for further 
analyses. MiR-34A-5p and miR-143-3p overexpression 
in BLM cells was validated by qPCR demonstrating a 
statistically significant miR overexpression of a three-
digit factor when compared to the mock vector (Figure 
2B). The strong overexpression of miR-143-3p led to a 
reduction of total CD44s protein in transient transfected 
BLM cells as well as in stable transfected WM1552C 
cells, while for miR-34A no reduction of CD44s protein 
was observed (Figure 2C).
To determine whether the miR based CD44s 
downregulation affects the sensitivity of melanoma to the 
therapy-relevant drug daunorubicin, the cell viability of 
untreated and daunorubicin-treated miR transfectants was 
determined. The reduced CD44s protein levels upon miR-
143-3p overexpression caused a statistically significant 
reduction of viable cells (propidium iodide (PI)/Annexin 
V double negative) and a statistically significant increase 
of early apoptotic cells (PI negative/Annexin V positive). 
The amount of late apoptotic cells (PI/Annexin V 
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double positive) was also increased, but not statistically 
significant (Figure 2D).
Furthermore, the miR-143-3p mediated CD44s 
downregulation also affected cell migration. Actually, the 
velocity [µm/min], the euclidean distance [µm] and the 
total accumulated distance [µm] were strongly reduced 
in the miR-143-3p overexpressing transfectants when 
compared to the other transfectants (Figure 2E–2G). Since 
miR-143-3p as well as miR-34A-5p reduced proliferation 
(Table 1), the proliferation of the transfectants was 
characterized. As shown in Figure 2H, both miR 
overexpressing transfectants exerted a statistically 
significant reduced proliferation rate in comparison to 
mock transfectants (Figure 2H).
The in vivo CD44s expression was also analyzed in 
non-affected skin sections (gluteal region) derived from 
61 human body donors by immunohistochemistry (IHC). 
CD44s expression was observed in the whole stratum 
germinativum, consisting of the stratum basale and the 
stratum spinosum. The stratum granulosum and stratum 
corneum were unreactive, which is in line with already 
published studies [40]. CD44s positive cells accumulated 
in the proliferative epidermis regions. The CD44s 
expression of the epidermal melanocytes was comparable 
to that of dermal keratinocytes ranging from weak (23/61), 
over medium (22/61) to strong (16/61) expression. 
Interestingly, the CD44s expression appears to correlate 
with the thickness of the stratum basale. Occasional 
CD44s positive spots were also visible within the dermis 
with a higher frequency within the stratum papillare than 
within the stratum reticulare (Figure 3A–3C). However, 
there existed no inverse correlation between the in vivo 
CD44s protein levels and the expression of miR-143-3p 
and miR-34A-5p determined by qPCR (Figure 3D). The 
expression levels of CD44s protein and miR-34A-5 as 
well as miR-143-3p were further correlated to clinical data 
of the investigated human body donors (Figure 3E–3J).
As a cell type specific CD44s expression was also 
analyzed in the context of benign melanocytic lesions 
(Table 2). Evaluating diverse subtypes of melanocytic 
nevi, CD44s expression levels ranged from medium to 
high. In detail, in the compound nevi type the CD44s 
expression was higher than in the deeper dermis localized 
dermal nevi type, but this effect was not statistically 
significant. In addition, the group of nevi with strong 
CD44s expression showed a lower mean age at diagnosis 
and a statistically significant higher amount of male 
patients (Figure 4E). When compared to the malignant 
melanoma probes, only in melanocytic nevi a statistically 
significant correlation between MART-1 and CD44s 
expression was detected (Figure 4A–4E).
The CD44s expression in human melanoma samples 
was correlated with known clinical characteristics (Table 
3). All investigated tumors exerted medium to high CD44s 
expression. Tumors with a medium CD44s expression 
level showed a more cytoplasmic localization, while 
tumors with high CD44s levels presented an additional 
membranous expression. In the adjacent epidermis, the 
CD44s expression was detected in cells of the stratum 
germinativum, but not within the stratum granulosum 
and stratum corneum, while cells in the dermis were also 
stained. In all cases analyzed the CD44 expression was 
stronger in melanoma cells when compared to the adjacent 
epidermal cells (Figure 5A–5B). In analogy to the skin 
Table 1: Published CD44 regulatory miRs and their tumor biological effects
tumor biological effect of the miR
miRs proliferation invasion apoptosis angiogenesis tumor suppressive/oncogenic
miR-143-3p ↓ ↓ ↑ ↓ tumor suppressive
miR-199a-3p ↓ ↓ ↑ ↓ tumor suppressive
miR-216a ↓ ↓ ↑ ↓ tumor suppressive
miR-328 ↓ ↓ ↑ ↓ tumor suppressive
miR-330 ↓ ↓ ↑ n.r. tumor suppressive
miR-34a-5p ↓ ↓ ↑ ↓ tumor suppressive
miR-373 controversial discussed
miR-491-5p ↓ ↓ ↑ ↓ tumor suppressive
miR-492 ↑ ↑ n.r. n.r. oncogenic
miR-512-3p ↓ ↓ ↑ n.r. tumor suppressive
miR-520c controversial discussed
miR-541-3p n.r. n.r. ↓ n.r. oncogenic
miR-608 ↓ ↓ ↑ n.r. tumor suppressive
miR-671 n.r. n.r. n.r. n.r. n.r.
miR-708 controversial discussed
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Figure 1: Establishment of a novel affinity based miR enrichment assay. (A) The workflow of the applied novel miR affinity 
purification assay is summarized. (B–G) The eluates and the respective amount of cell lysate (input) were analyzed by qPCR as described 
in Materials and Methods. As internal positive control the enrichment of miR-152 with the HLA-G 3’ UTR as bait was determined (B) as 
well as negative control (C) the absent enrichment of miR-141, which was detected in the applied cell lysates (input). Furthermore, the 
exemplary validation of the known CD44 regulatory miRs; miR-34-5p (D), miR-143-3p (E), miR-199A-3p, and miR-491-5p (G) is shown.
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samples of the human body donors as well as the benign 
melanocytic lesions, the CD44s protein and the miR-34A-
5p expression levels as well as miR-143-3p expression 
levels showed no inverse correlation (Figure 5C). For 
a better visualization of the melanoma cells, MART-1 
expression was determined by immunohistochemistry. 
MART-1 expression levels in the malignant melanoma 
ranged from low to high (Figure 6A–6C) without any 
correlation between the MART-1 and CD44s expression 
levels (Figure 6D).
Figure 2: Modulation of tumor biological relevant functions by miR-143-3p-mediated CD44s downregulation. (A) The 
membranous CD44s expression of 10 human melanoma cell lines was quantified by flow cytometry and exemplary visualized for one of 
three biological replicates as overlay. The grey histograms represent the isotype control and the black histogram staining with the specific 
CD44s antibody as described in Materials and Methods. (B) The functionality of the miR expression vectors was validated by qPCR 
after transient transfection in the human melanoma cell line BLM as described in Materials and Methods. (C) Western blot analyses of 
transiently miR-143-3p transfected BLM cells as well as of stably transfected WM1552C cells were performed using a CD44 specific 
antibody. (D) Flow cytometry based Annexin V and propidium iodide (PI) staining for daunorubicin mediated apoptosis in the miR-143-3p 
transfectants was performed. (E–H) Cell migration, in particular euclidean distance (E), accumulated distance (F), and velocity (G) as well 
as proliferation (H) was analyzed in the transfectants.
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Based on the recently described immune cell 
infiltration and marker analysis [34], an almost statistically 
significant (p = 0.057) correlation of CD44s expression 
with PD-L1 (B7-H1) was found in the MM samples 
analyzed, while partially statistically significant inverse 
correlation between CD44s protein levels and infiltrating 
immune effector cells, like CD4+ cells (p = 0.18), CD8+ 
cells (p = 0.03), and CD68+ M1 macrophages (p = 0.1) was 
observed. There existed no correlation between CD44s 
protein levels and the infiltrating regulatory FOXP3+ 
T cells, M2 macrophages (CD123), and dendritic cells 
(CD11c and CD123; Figure 5D). Furthermore, no effect 
of the CD44s protein levels, the tumor thickness (Breslow 
value) and the pT stadium could be observed (Figure 5D).
DISCUSSION
During the last years, the number of publications 
reporting miR target interactions is steadily increasing. 
Often, studies describe many different miRs against one 
certain target mRNA in complete different cell systems 
under varying conditions with marginally comparable 
methods. There, the role of known CD44-regulatory 
miRs was analyzed in melanoma. The inhibition of CD44 
using anti-CD44 antibodies as anti-melanoma treatment 
showed success in an experimental study [41], while a 
recent phase I clinical trial of an anti-CD44 humanized 
antibody using the RG7356 in patients with metastatic 
or locally advanced CD44-expressing solid malignancies 
(6 melanoma from 65 different solid tumors of various 
entities) only demonstrated a modest anti-tumor activity 
[42] demanding alternative strategies to overcome CD44 
expression in tumors. In this context, a miR-based down 
regulation of CD44 might be a better therapeutic tool. This 
approach extends the activity of all CD44 splice variants, 
since the 3’ UTR of CD44 splice variants is equal. In 
contrast, therapeutic antibodies potentially do not bind 
to all of the different CD44 splice variants and thus their 
binding may not completely inhibit the biological function 
of CD44.
First, the affinity of the 15 known miRNAs binding 
to the CD44 3’ UTR was determined using a novel 
modified miTRAP technique. While the original miTRAP 
technology is based on interaction between MS2 tagging 
and a not commercial-available fusion protein containing 
the MS2 loop binding protein and the maltose binding 
protein, the in vitro transcribed 3’ UTRs were not tagged 
with MS2 loops and loaded out amylose beads, but were 
polyadenylated and coupled to commercial-available oligo 
dT coated beads. To avoid the binding of polyadenylated 
mRNA species also present in the cell lysate, the lysates 
were purified prior usage by size exclusion columns (≤ 75 
nt). This miR containing flow through was used for later 
affinity purification. The functionality of this modified 
Table 2: Melanocytic nevi patient’s characteristics
patient no. age at diagnosis [years] sex type of nevus
1 13 male compound
2 51 male compound
3 72 female dermal
4 72 female dermal
5 41 female dermal
6 76 female dermal
7 27 female dermal
8 27 female compound
9 55 female dermal
10 45 female dermal
11 81 female dermal
12 37 female dermal
13 37 female dermal
14 44 female compound
15 13 male dermal
16 44 female compound
17 42 male compound
18 59 female compound
19 31 female compound
20 54 male dermal
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Figure 3: Differential CD44s expression in healthy skin sections. (A–C) A representative immunohistochemical staining of 
human skin samples derived from human body donors with distinct CD44s expression shown. The staining was scored as weak, medium, 
and strong expression. (D) qPCR analyses of human skin samples with distinct CD44s expression levels was used to determine the absolute 
miR-34a-5p and miR-143 absolute copy number as described in Materials and Methods. (E–J) The expression levels of CD44s protein (E, 
F), miR-34A-5p (G, H), and miR-143-3p (I, J) were correlated to selected clinical parameters from the human body donors.
Oncotarget6516www.oncotarget.com
miTRAP technique was validated by the enrichment of 
the miR-152 with the HLA-G 3’ UTR as bait (positive 
control), while the miR-141 was present in the applied cell 
lysate (input), but neither enriched (negative control; [43] 
with the HLA-G 3’ UTR nor with the CD44 3’ UTR.
Four of 15 CD44-regulatory miRs were enriched 
using the CD44 3’ UTR as bait, which due to its size was 
divided into two overlapping fragments. With respect to 
their abundance in the cell lysate (input), miR-34A-5p and 
miR-143-3p exerted the highest affinities for the CD44 3’ 
UTR. However, only miR-143-3p overexpression caused 
a downregulation of CD44s protein linked to a decreased 
proliferation and cell migration as well as an enhanced 
sensitivity for daunorubicin-induced apoptosis. This 
is in line with the association of CD44 overexpression 
with tumor progression and metastasis in various human 
cancers including melanoma. Furthermore, patients with 
high CD44 expression levels in malignant melanoma 
have a statistical significantly decreased 5 years’ OS in 
comparison to the CD44 low group [29].
Figure 4: Demonstration of the CD44s and the corresponding MART-1 expression in human melanocytic nevi. (A–D) 
Immunohistochemical staining for CD44s demonstrated either medium (A) or high (C) CD44s expression in the melanocytic nevi, as well 
as the corresponding MART-1 expression. (E) Correlation of the CD44s expression level with clinical parameters, including sex, age at 
diagnosis, type of nevi (compound type or dermal), and the correlation to the MART-1 expression. 
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In addition, CD44 expression almost statistically 
significantly correlated with PD-L1 expression and 
with a trend can inverse correlation to tumor infiltrating 
pro-inflammatory immune effector cells. Despite the 
PD-1 checkpoint inhibitor pembrolizumab is used for 
melanoma therapy [44] and the PD-L1 checkpoint 
inhibitor atezolizumab is still under investigation in 
ongoing clinical trials with melanoma patients, the success 
Figure 5: Correlation of the CD44s expression in human malignant melanoma with miR expression and immune cell 
infiltration and its tumor biological impact. (A–B) Immunohistochemical staining for CD44s demonstrated either medium (A) or 
high (B) CD44s expression in the malignant melanoma samples. (C) Correlation of miR-34A-5p and miR-143-3p with the CD44s protein 
levels in malignant melanoma samples. (D) Correlation of CD44s expression levels to clinical parameters from the melanoma patients and 
to infiltrating immune effector cells [34].
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Table 3: Malignant melanoma patient’s characteristics
patient 
no.
age at diagnosis 
[years] sex ulcerated
Breslow 
[mm]
pT 
stadium type of melanoma recurrence
1 71 male no 2.15 3 superficial spreading melanoma no
2 62 female yes 1.1 2 superficial spreading melanoma no
3 82 male yes 3.5 3 nodular melanoma yes
4 50 male yes 2.6 3 nodular melanoma no
5 64 male no 3.2 3 superficial spreading melanoma no
6 51 female no 1.11 2 superficial spreading melanoma no
7 88 female no 7.05 4 nodular melanoma no
8 75 male no 1.3 2 superficial spreading melanoma no
9 80 male yes 3.5 3 nodular melanoma no
10 64 female no 10 4 nodular melanoma unknown
11 42 female yes 6.1 4 nodular melanoma no
12 53 male yes 14.2 4 nodular melanoma yes
13 59 male no 1.8 2 superficial spreading melanoma no
14 75 female yes 3.08 3 nodular melanoma yes
Figure 6: MART-1 expression and its correlation with CD44s expression in malignant melanoma. (A–C) 
Immunohistochemical analysis was performed with a MART-1 specific mAb to determine MART-1 expression in human malignant 
melanoma samples. A heterogeneous MART-1 expression was found ranging from low (A), medium (B) or high (C) MART-1 expression 
in all investigated melanoma samples. (D) MART-1 and CD44s expression levels were correlated.
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Table 4: List of the applied antibodies
name method dilution species manufacturer
anti-CD44s (156-3C11) mAb IHC, WB 1:1000 mouse Thermo-Fisher Scientific
HRP-linked anti-Mouse IHC - goat DAKO
HRP-linked anti-mouse WB 1:1000 goat dianova
anti-GAPDH (14C10) mAb WB 1:12000 rabbit Cell Signaling
HRP-linked anti-rabbit WB 1:12000 goat Cell Signaling
anti-CD44 (156-3C11) FITC mAb FACS mouse biotechne
Table 5: List of the applied oligonucleotides
name application sequence (5′ → 3′) condition
Klon3UTR-#A fw cloning GTGTAACACCTACACCATTATC 60°C
Klon3UTR-#A rev cloning GCAAAGCCTTTCACAGGAGAG 60°C
Klon3UTR-#B fw cloning CCTGTCCTGGAATCAGAGTTG 60°C
Klon3UTR-#B rev cloning TTGGTGTTGTTATGAATCTC 60°C
Kl3UTRHLAGfw cloning AAACAGCTGCCCTGTGT 60°C
Kl3UTRHLAGev cloning AAAGTTCTCATGTCTTCCATTT 60°C
708-5pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACCCCAGC 42°C
708-5p PCR fw qPCR GCCCAAGGAGCTTACAATCTA 60°C
671-5pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACCTCCAG 42°C
671-5p PCR fw qPCR GCCCAGGAAGCCCTGGAGGGG 60°C
608RT-PCR stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACACGGAG 42°C
608 PCR fw qPCR GCCCAGGGGTGGTGTTGGGACAG 60°C
541RT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACAGTCCA 42°C
541 PCR fw qPCR GCCCTGGTGGGCACAGAATC 60°C
520c-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACACCCTC 42°C
520c-3p PCR fw qPCR GCCCAAAGTGCTTCCTTTTA 60°C
512-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACGACCTC 42°C
512-3p PCR fw qPCR GCCCAAGTGCTGTCATAGCT 60°C
491-5pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACCCTCAT 42°C
491-5p PCR fw qPCR GCCCAGTGGGGAACCCTTCC 60°C
373-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACACACCC 42°C
373-3p PCR fw qPCR GCCCGAAGTGCTTCGATTTTG 60°C
330-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACTCTCTG 42°C
330-3p PCR fw qPCR GCCCGCAAAGCACACGGCCTG 60°C
328-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACACGGAA 42°C
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is limited and patients develop resistances over treatment. 
Thus, targeting might be a promise therapeutic tool for 
malignant melanoma.
Due to the fact of high CD44 expression levels 
in various tumor diseases, anti-CD44 antibodies are 
currently under investigation as potential anti-tumoral 
immune therapeutics in different animal studies to reduce 
tumor progression [45]. However, an antibody based anti-
CD44 therapy will face certain limitations such as (i) 
the existence of different CD44 splicing variants lacking 
several protein domains and (ii) the fact that CD44 is 
also expressed in various healthy tissues. In contrast, 
miR-based CD44 inhibition limited to malignant cells 
would affect all CD44 splice variants, since they share 
the same 3’ UTR. Recent studies report the functionality 
of miRs linked to antibodies directed against cell surface 
molecules, like membranous tumor antigens and receptors. 
After binding of the antibody to the tumor antigen on the 
cell surface, which already blocks its functionality, the 
following internalization of this complex further enables 
the miR-induced effects like downregulation of tumor 
relevant genes [46].
A prerequisite is, however, that only miRs are 
applied for such strategies, which are able to down-
regulate the translation of the gene of interest. Therefore, 
this study aimed to identify the most potent CD44-
regulatore miRs published so far in melanoma with the 
highest potential for miR-143-3p. However, concluding 
from the missing inverse correlation of miR-143-3p and 
CD44s expression in healthy and malignant skin tissues as 
well as in the investigated melanoma cell lines (data not 
shown), miR-143-3p is able to inhibit CD44 translation 
328-3p PCR fw qPCR GCCCCTGGCCCTCTCTGCCC 60°C
216a-5pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACTCACAG 42°C
216a-5p PCR fw qPCR GCCCTAATCTCAGCTGGCAA 60°C
199a-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACTAACCA 42°C
199a-3p PCR fw qPCR GCCCACAGTAGTCTGCACAT 60°C
152RT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACCCAAGT 42°C
152 PCR fw qPCR GCCCTCAGTGCATGACAGA 60°C
143-3pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC ACTGGATACGACGAGCTA 42°C
143-3p PCR fw qPCR GCCCTGAGATGAAGCACTG 60°C
34a-5pRT-Rct stem-loop primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACACAACC 42°C
34a-5p PCR fw qPCR GCCCTGGCAGTGTCTTAGCT 60°C
stem loop reverse primer qPCR GTGCAGGGTCCGAGGT 60°C
Klon2miR-34a fw cloning AAACTCGAGgagacagttgctgaaggt 60°C
Klon2miR-34a rev cloning AAAGGATCCctgcaagacggggttaat 60°C
Klon2miR-143 fw cloning AAACTCGAGaaactggtctgcccaggacta 60°C
Klon2miR-143 rev cloning AAAGGATCCtgggtgatggagtgagactgt 60°C
invitroHLA-Gfw PCR CCCCCCTAATACGACTCACTATAGGGAAAA AACAGCTGCCCTGTGT 60°C
invitroHLA-Grev PCR TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTAAAGTTCTCATGTCTTCCATTT 60°C
ivCD443Afw PCR CCCCCCTAATACGACTCACTATAGGGAA AGTGTAACACCTACACCATTATC 60°C
ivCD443Arev PCR TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTGCAAAGCCTTTCACAGGAGAG 60°C
ivCD443Bfw PCR CCCCCCTAATACGACTCACTATAGGGAAA CCTGTCCTGGAATCAGAGTTG 60°C
ivCD443Crev4 PCR TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTGGTGTTGTTATGAATCTC 60°C
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and function upon overexpression, but does not seem to 
be the key regulating miR in the in vivo cellular situation. 
Hence, the authors hypothesize that other so far unknown 
CD44 regulatory miRs may exist, which could even exert 
a stronger potential on the CD44 translational inhibition. 
Indeed, since the beginning of the present study other 
CD44-regulating miRs have been reported. These novel 
miRs have not been considered within the present study. 
To improve studies identifying single miRs regulating 
CD44 or even other proteins, the authors suggest to apply 
the novel miR affinity purification method presented 
in this study in combination with next generation 
sequencing to identify a large panel of miRs binding to 
the 3’ UTR of CD44. These could then be used for further 
functional studies.
Furthermore the authors want to advise that instead 
of CD123 as a marker for M2 macrophages the markers 
CD162 and/or CD203 would be even better markers.
MATERIALS AND METHODS
Cell culture and treatment
The melanoma cell lines A-375, BLM, BUF-1088, 
BUF-1268, IGR-1, MEVO, MV-3, WM-9, WM-35 and 
WM-1552C and the CD44 negative human embryonal 
kidney cell line HEK293T were cultured in Dulbecco’s 
modified Eagles medium (DMEM; Merck Millipore, 
Heidelberg, Germany) supplemented with 10% fetal calf 
serum (FCS; Merck Millipore, Heidelberg, Germany), 1% 
penicillin/streptomycin (Sigma Aldrich, St.Louis, USA), 
1% sodium pyruvate (Merck Millipore, Heidelberg, 
Germany), 2 mM L-glutamine (Merck Millipore, 
Heidelberg, Germany) and detached with trypsin (Sigma 
Aldrich, St.Louis, USA).
Human samples analyzed
Random human skin tissues were collected from 
human body donors (n = 65) in the Institute of Anatomy 
and Cell Biology, Martin Luther University Halle-
Wittenberg, Halle, Germany from 2015 to 2018. In 
addition, tissue samples of human melanocytic nevi (n 
= 20) archived between 2010 and 2014 in the Institute 
for Pathology of the Martin Luther University Halle-
Wittenberg were selected as non-malignant melanocytic 
lesions. Archived tissue samples of cutaneous MM 
samples collected between 2008 to 2016 were provided 
from the Department of Dermatology, Paracelsus 
Medical University, Salzburg, Austria as well as from 
the Department of Dermatology, University Hospital 
of Zurich, Zurich, Switzerland [34]. This study was 
performed according to the principles expressed in the 
declaration of Helsinki. Clinical data of MM patients 
and the composition of immune cell infiltration of the 
respective tumor lesions were available [34].
Flow cytometry
Cell surface associated protein levels, proliferation 
rate and frequency of apoptosis were analyzed in 
human melanoma cell lines by flow cytometry with the 
MACSQuant® Analyzer 10 (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Data analysis was performed using 
the Flowing Software (Cell Imaging Core, Turku Centre 
for Biotechnology, Finland). For CD44s detection, the 
mouse monoclonal antibody (mAb) CD44 (156-3C11) 
[FITC] (Bio-Techne, Wiesbaden, Germany) was utilized. 
Apoptosis was monitored with the Annexin-V-FITC 
Apoptosis-Detection-Kit (Beckman Coulter, Brea, CA, 
USA) following the manufacturer´s instructions.
Cloning of miR expression vectors and cell 
transfection
The miR expression vectors were generated by 
cloning the miR gene with its flanking regions into 
the multiple cloning site of the pmR-m-Cherry vector 
(Clontech, Mountain View, CA, USA). After sequencing, 
the vectors were transiently transfected into human 
melanoma cell lines using Viromer® RED (Lipocalyx, 
Halle, Germany). The BLM cells were transfected 
transiently. Due to the very low transfection efficacy of 
the WM1552C cells, these cells were transfected stably by 
geneticin supplemented medium (500 µg/ml).
Cell biological assays
Cell proliferation, migration and apoptosis were 
determined in miR overexpressing cells 24 h after 
transfection. Briefly, 1 × 105 transfected cells/well were 
seeded and grown in complete DMEM medium. The cell 
proliferation was assessed by determination of the total 
cell number after 24 h, 48 h, 72 h and 96 h of culture. For 
investigating chemotherapy sensitivity, cells were treated 
with 1 µg/ml daunorubicin (Sigma Aldrich, St.Louis, 
USA) for 2 h, washed three times with PBS and then 
cultured for additional 24 h prior to analysis.
An undirected migration assay was performed using the 
CytoSMART™ System (Lonza, Basel, Switzerland) by seeding 
4 × 104 cells 48 h after transient transfection into standard T75 
cell culture flasks (Sarstedt, Nürmbrecht, Germany) with 
fresh medium. After 4 h adherence, the migration assays were 
started by recording a picture every 5 min for a total of 6 h. 
For data evaluation the software Tracking Tool™ PRO v2.0 
(Gradientech, Uppsala, Sweden) was applied.
Nucleic acid isolation, cDNA synthesis and qPCR
DNA was isolated from different human cell lines 
using the NucleoSpin® Tissue kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer`s 
instructions. Total RNA was extracted from non-affected 
human skin tissue samples derived from formalin fixed 
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human body donors (gluteal region) with peqGold TriFast 
(VWR International, Darmstadt, Germany) according to 
the manufacturer’s instructions followed by RQ1 RNase-
free DNase I treatment (Promega, Mannheim, Germany). 
For miR-specific cDNA synthesis, 1 µg of total cellular 
RNA was reverse transcribed with miR-specific stem loop 
primers [35, 36] and the RevertAidTM H Minus reverse 
transcriptase (Thermo-Fisher Scientific, Waltham, USA).
For qPCR target-specific primers and the iQ™ 
SYBR® Green Supermix (Biorad, Hercules, USA) were 
applied. Subsequently, the reactions were run in a qTOWER3 
G (Analytik Jena, Jena, Germany). Absolute copy numbers 
were measured against an external miR-specific TOPO-
TA plasmid standard (Invitrogen, Carlsbad, CA, USA) 
containing the respective PCR product [37, 38]. Reactions 
were performed in triplicates of biological replicates and 
results are described as mean values with standard deviation 
and t-test. All oligonucleotides used are listed in Table 5.
Western blot
Proteins of transiently transfected cells were extracted 
48 h after transfection as recently described [50]. 30 µg of 
total protein/lane were loaded on Novex™ 4–20% Tris-
Glycine Mini Gels, WedgeWell™ (Invitrogen, Carlsbad, 
CA, USA). After electrophoresis, the separated proteins 
were blotted onto a 0.2 μm nitrocellulose membrane (GE 
Healthcare, Little Chalfont, UK) for 2 h at 150 mA/gel. 
The blots were then blocked for 2 h at room temperature 
followed by incubation with primary antibodies over night 
at 4°C. After 5 washing steps the blots were incubated with 
the secondary antibodies and bands were visualized with the 
Amersham ECL Prime Western Blotting Detection reagent 
(Amersham, Chalfont St Giles, UK) on a ChemiDoc Touch 
Imaging system (Biorad, Hercules, USA). All applied 
antibodies used are listed in the Table 4.
Immunhistochemistry
Standard immunohistochemistry was performed to 
assess the CD44 protein expression in the diverse formalin 
fixed human skin tissues. Briefly, 5 µg sections of paraffin 
embedded blocks were deparaffinized and hydrated prior 
to epitope retrieval treatment with HIER citrate buffer 
(Zytomed Systems, Berlin, Germany) for 20 min at 95°C. 
Endogenous peroxidases were blocked by incubation 
with 1% (V/V) H2O2 for 20 min at room temperature, 
before serum (Agilent, Santa Clara, USA) for 1 h at room 
temperature and incubated with the primary CD44 antibody 
overnight at 4°C. Negative controls were incubated solely 
in TBS-T. After washing steps, the HRP-linked secondary 
antibody was added. The detection was performed with 
the DAB liquid kit (Dako, Santa Clara, USA) and finally 
the reaction was quenched by immersion in tap water. 
After haematoxylin staining and dehydration, the slices 
were mounted with Eukitt® mounting medium (ORSAtec, 
Bobingen, Germany). All applied antibodies used are listed 
in the Table 4. The photo documentation was performed 
with a DMi8 microscope (Leica, Wetzlar, Germany). The 
CD44s expression was scored by two researchers (J.F. and 
S.J.B.) as follows: 1 – weak, 2 – medium, and 3 – strong.
Modified miR enrichment assay
To enrich CD44-specific miRs, the miTRAP 
technology [39] was modified. Briefly, the 3‘ UTR of 
CD44 was splitted into two overlapping fragments (#A, 
#B), which were in addition to the 3‘ UTR of HLA-G as 
an internal positive control amplified by PCR (Taq DNA 
Polymerase, Thermo Fisher Scientific) from genomic DNA 
and cloned into a TOPO™ TA Cloning™ Vector (Thermo 
Fisher Scientific). After sequencing of the respective 3’ 
UTRs, they were again amplified with specific primers 
containing the T7 promoter sequence within the forward 
primer for further in vitro transcription and the signal for a 
later poly(A) tail after in vitro transcription in the reverse 
primer. The resulting PCR products were purified by 
agarose gel electrophoresis. Subsequently, the purified PCR 
products were applied as templates for in vitro transcription 
over night using the T7 RiboMAX™ Kit (Promega, 
Madison, WI, USA). After DNase I digestion (Promega, 
Madison, WI, USA) the in vitro transcribed RNA constructs 
were purified with the MEGAclear Transcription Clean-Up 
Kit (Thermo Fisher Scientific) according to the manual.
The miR purification assay was performed in 
analogy to the previously published miTRAP assay with 
modification [37]. Instead of the fusion protein consisting 
of a MS2 loop and maltose binding protein in combination 
with amylose beads, the in vitro transcribed 3’ UTRs 
serving as baits for miR enrichment were polyadenylated 
and then linked to magnetic Dynabeads™ Oligo(dT)25 
(Thermo Fisher Scientific). Furthermore, any containing 
polyadenylated RNA species, e.g. mature mRNAs, present 
in the applied cell lysate used as input were excluded prior 
usage by size exclusion columns (NucleoSpin® miRNA, 
MACHEREY-NAGEL, Dürren, Germany). The principle 
of this assay is summarized in Figure 1A.
Statistical analyses
Microsoft Excel 2016 (Microsoft Corporation, 
Albuquerque, USA) and OriginPro 2017 (OriginLab, 
Northampton, USA) were used for calculation of mean, 
standard deviation and students’ test under assumption of 
unequal variance. Data were significant with p-values of p < 
0.05 and marked as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
CONCLUSIONS
The tumor suppressive miR-143-3p was identified 
as the most potent CD44 inhibitory miR, which affects 
growth characteristics of melanoma cells suggesting the 
implementation of miR-143-3p as as a potential anti-CD44 
therapy of malignant melanoma.
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